Skip to main content

Table 1 Gene expression changes induced by SAHA or NaB treatment vary in fold change but not (+/-) directionality and are consistent with G1 arrest, suppression of stem/progenitor and activation of neuronal lineage commitment programs

From: Histone deacetylase inhibitors SAHA and sodium butyrate block G1-to-S cell cycle progression in neurosphere formation by adult subventricular cells

Genes Upregulated compared to vehicle control

Gene Symbol

Name

SAHA

NaB

Ctnnb1

Catenin, beta-1

1.31 ± 0.02

1.82 ± 0.34

Gli1

glioma-associated oncogene

5.26 ± 1.90

4.19 ± 2.77

Neurod1

Neurogenic differentiation1

4.28 ± 1.78

1.45 ± 0.60

Neurog1

Neurogenin 1

9.86 ± 4.35

2.79 ± 1.38

Tcf4

Transcription factor 4

1.50 ± 0.34

1.09 ± 0.18

p21 (Cdkn1a)

Cyclin-dependant kinase inhibitor 1a

5.48 ± 2.98

3.35 ± 0.99

p27 (Cdkn1b)

Cyclin-dependant kinase inhibitor 1b

2.70 ± 0.64

2.34 ± 0.31

p57 (Cdkn1c)

Cyclin-dependant kinase inhibitor 1c

1.89 ± 0.48

3.33 ± 1.17

Shh

Sonic hedgehog

41.57 ± 6.98

6.31 ± 2.37

Genes Downregulated compared to vehicle control

Gene Symbol

Name

SAHA

NaB

Ascl1

Achaete-scute complex homolog 1

-2.36 ± 0.71

-3.43 ± 0.92

Cdk2

Cyclin-dependant kinase 2

-4.64 ± 1.91

-8.37 ± 5.87

Cdk4

Cyclin-dependant kinase 4

-3.35 ± 0.70

-4.18 ± 0.17

Ccnd1

Cyclin D1

-1.55 ± 0.63

-1.87 ± 0.17

Hes1

Hairy/enhancer of split, Drosophila homolog of, 1

-3.89 ± 1.90

-5.56 ± 0.57

Hes5

Hairy/enhancer of split, Drosophila homolog of, 1

-11.87 ± 1.18

-23.85 ± 3.15

c-Myc

V-myc avian myelocytomatosis viral oncogene homolog

-1.92 ± 0.77

-2.44 ± 1.05

Olig2

Oligodendrocyte lineage transcription factor 2

-1.06 ± 0.03

-2.83 ± 1.71

Pax6

Paired box gene 6

-2.04 ± 1.18

-4.22 ± 1.92

Sox1

SRY-box 1

-4.46 ± 3.33

-4.96 ± 2.52

Sox2

SRY-box 2

-3.08 ± 1.60

-3.44 ± 1.06

Sox9

SRY-box 9

-2.35 ± 0.25

-1.24 ± 1.06

  1. +/- fold-changes in gene expression in adult mouse NSCs treated with SAHA or NaB were calculated from vehicle controls from ≥ 3 independent qRT-PCR trials